Press The Biocodex Group strengthens its leadership in the treatment of constipation with the acquisition of the pharmaceutical speciality Transulose® from Teva Santé
The Biocodex Group strengthens its leadership in the treatment of constipation with the acquisition of the pharmaceutical speciality Transulose® from Teva Santé
Biocodex, the French pharmaceutical group with expertise in Microbiota, Women’s Health and Orphan Diseases, announces that it has acquired the Transulose specialty from Teva Santé, French subsidiary of the Teva Group, on 24 April 2024.
Transulose® is a drug in the osmotic laxative category.
Transulose® has been marketed in France for almost 30 years. It will complement the Biocodex Group’s portfolio, which already includes several specialties, such as Ultra Levure®, Melaxose®.
The transfer of the marketing authorization has been approved by the health authorities, and the product is already available from pharmaceutical wholesalers.